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Poster Session I 65Of note, among these 23 pts, 11 are alive at a median of
40.5 months (range 13.5–91) after relapse. Two of these patients
subsequently underwent a nonmyeloablative transplant and are
alive - one at 51.7 months and the other at 18.7 months after non-
myeloablative transplant. The nine other pts have received a spec-
trum of chemotherapy agents after relapse. Conclusion: ASCT is
a safe and effective strategy in the management of MCL. The en-
couraging results observed for pts undergoing ASCT in first remis-
sion merit further prospective evaluation. A subset of pts tends to
have a prolonged survival despite relapsing after ASCT. The clinical
characteristics pre and post ASCT do not reveal an obvious cause
for the same. It is likely that the ongoing work in gene expression
profiling and study of signaling pathways may identify multiple mo-
lecularly and clinically distinct diseases within what is considered
a single disease entity.
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LONG TERM FOLLOW-UP REPORT ON AUTOLOGOUS STEM CELL
TRANSPLANT (ASCT) FOR MULTIPLE MYELOMA (MM) AND EVALUA-
TION OF PROGNOSTIC FACTORS: PROLONGED SURVIVAL FOR PATIENTS
WITH LOW HEAMTOPOIETIC CELL TRANSPLANTATION-COMORBITD-
ITY INDEX (HCT-CI) SCORE
Farhat,M., Kassar,M., Gregory, S.A., Venugopal, P.,Myint, R., Go, A.,
Maciejewski, J., Fung, H.C. Rush University Medical Center, Chicago,
IL.
Background: Up-front ASCT is the standard of care for eligible
patients with symptomatic MM. However, there is a lack of long
term follow up data on patient with multiple myeloma from time
of diagnosis. Objective: Evaluation of prognostic factors including
the HCT-CI on mortality risk after autologous stem cell transplant
(ASCT) in multiple myeloma (MM).Methods:We conduct a retro-
spective analysis on 79 patients (pts) with multiple myeloma whom
been followed since original diagnosis between 01/1983 to 12/2003.
The median time from diagnosis to ASCT was 7.6 months. All of
which underwent ASCT in our institution with a median follow
up after ASCT of 45 months. All pts received with induction che-
motherapy before ASCT consisting of various combinations of vin-
cristine, adriamycin, dexamethasone, thalidomide, melphalan,
BCNU, and cyclophospamide. The median CD34 cells collected
was 5.05  106/Kg, with a median hospital stay at transplant of 17
days. Pts were also retrospectively assigned scores based on the
HCT-CI. Definitions of comorbidities were previously reported
(Sorror et. al. Blood 2005; 106:2912). Results: The group com-
prised 50% male with a median age was 55 years (38 – 73). 55 pts
had single transplant and 24 pts had a tandem ASCT. The majority
of pts had IgG myeloma (62 pts.). Comorbidities index showed an
HCT-CI score of 0 in 30%, 1 in 30%, 2–8 in 40% of the pts,
with a median score of 1.77. 20 patients died with only one due to
treatment related mortality (TRM). Pts were categorized into 2
groups: low-risk (scores of 0–1), 46 pts. High-risk (scores 2–8), 33
pts. Neither age, gender, hospital during at transplant, prior
chemo-regimen, or pre-conditioning regiment, amount of CD34
cell collected, nor myeloma subtype, had an significant impact on
OS. By using Kaplan meier survival estimates, the 5 yrs overall sur-
vival (OS) from time of diagnosis comparing the low risk and high
risk group using the HCT-CI, were 82% and 53% respectively (P
5 0.03). Using a cox regression model, the low risk group has a sur-
vival advantage (HR5 2.69, P5 0.03). The median OS for the high
risk group was 63.7 month while it was not reached for the low risk
group. Conclusion: We conclude that in this cohort with adequate
follow-up: 1) HCT-CI score is the only predictive factor for survival
irrespective of other compounding factors and 2) prolonged survival
can be achieved in the subgroup of pts with low HCT-CI score.
176
PHASE I/II TRIAL OF BORTEZOMIB MAINTENANCE FOLLOWING AUTOL-
OGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION AS
TREATMENT FOR INTERMEDIATE- AND ADVANCED-STAGE MULTIPLE
MYELOMA
Schiller, G.J., Liao, M., Sohn, J.P., Malone, R., Bartoni, K.,
Habtemariam, B., Paquette, R., De Vos, S., Territo, M. University of
California, Los Angeles, Los Angeles, CA.Pts with intermediate- and advanced-stage multiple myeloma
were assigned to maintenance therapy with bortezomib beginning
a minimum of 3 and a maximum of 4 mos after the day of autologous
PBPC transplantation following a standard preparative regimen of
high-dose melphalan. Eligibility for the initiation of maintenance
required nl organ function with post-transplant neutrophil and plt
recovery. Cohorts of 3 pts each were entered at 1 of 3 dose levels
of bortezomib (1.0, 1.3, and 1.6 mg/m2) given IV q wk for 3 wks fol-
lowed by a 1-wk rest period constituting 1 treatment cycle for a total
of 8 cycles. To-date, 29 pts were eligible for study treatment and 23
pts received at least 1 dose of maintenance. The median t from di-
agnosis to transplant was 11.4 mos and the median t from autolo-
gous transplant to the initiation of bortezomib maintenance was
3.7 mos. Protocol adherence was excellent with only 1 pt missing
the final dose of treatment and 1 other pt discontinuing therapy
due to personal reasons. After completion of the Phase I portion
of the study, the DLT was determined to be 1.6 mg/m2 based on
grade 3 diarrhea in 2 pts. All subsequent pts entered were treated
at the MTD of 1.3 mg/m2. Other, non-dose-limiting toxicities in-
cluded thrombocytopenia, neuropathy, anemia, fatigue, neutrope-
nia, musculoskeletal pain, nausea, herpes zoster reactivation,
diarrhea, edema, and cough. Disease assessment consisted of serum
and urine PEP and bone surveys as well as bone marrow aspiration
for those pts with nonsecretory myeloma. 2 pts required termina-
tion of the study drug due to unacceptable side effects. 2 separate
pts terminated the study due to disease progression. 1 additional
pt discontinued further study treatments due to personal reasons.
All 23 pts are eligible for response assessment. 13 pts continue to
be followed for disease recurrence in the post-treatment period
while 4 others continue on treatment. After a median follow-up
from transplantation of 17.1 mos, 6 pts have relapsed while none
have died of recurrent myeloma. The current median relapse-free
survival is 15.8 mos. This phase I/II trial demonstrates that bortezo-
mib can be safely administered as maintenance after conventional
autologous PBPC transplantation with an MTD of 1.3 mg/m2 given
3 times per month for 8 mos. These preliminary results, when com-
pared to published results of autologous transplantation for mye-
loma, suggest that bortezomib maintenance may favorably impact
t-to-recurrence.177
THE ‘‘SIDE-POPULATION’’ IN HUMAN LYMPHOMA CELL LINES HAVE IN-
CREASED CHEMO-RESISTANCE, STEM-LIKE PROPERTIES, AS A TARGET
FOR IMMUNOTHERAPY
Shafer, J.A.1,2, Bollard, C.M.1,2, Leen, A.M.1,2, Rooney, C.M.1,2,
Brenner, M.K.1,2, Foster, A.E.1,2. 1Baylor College of Medicine; 2Baylor
College of Medicine, Houston, TX.
We previously demonstrated that cancer cells contain a distinct
‘‘side-population’’ (SP), characterized by active transport of
Hoechst fluorescent dye. The mechanisms responsible for Hoechst
efflux also contribute to resistance to chemotherapy. This popula-
tion has been shown to be enriched for tumor initiating cells in sev-
eral human cancer models. We hypothesize that targeting the
cancer ‘‘SP’’ cells using immunotherapy will eliminate the cell pop-
ulation least sensitive to chemotherapy and enriched for tumor re-
populating potential which may prevent relapse. In this study we
characterize SP cells in ten Human Lymphoma Cell Lines. We
show that that 5 of the 10 lymphoma cell lines tested (HDLM2,
L428, Ramos, Toledo, Karpas) had a distinct SP ranging from
0.8–2%. In vitro these SP cells can repopulate both the SP and
non-SP cells. Gene expression analysis of the SP showed increased
expression of ABCG2 and other ABC transporters that mediate
both the transport of Hoechst dye and other drugs including
some chemotherapeutic agents out of the cell. Further, we demon-
strated that cell lines with a SP are resistant to the chemotherapeutic
drug gemcitabine, and within these lines it the SP cells that are pref-
erentially resistant to this agent. The cell lines that did not have SP
showed either complete or partial sensitivity to this drug. In addi-
tion, we demonstrated that the SP population is enriched for the
cancer testis antigen’s MAGE-4, SSX2 and NY-ESO. These anti-
gens are attractive targets for cytotoxic T lymphocyte therapy since:
they are immunogenic, have restricted expression in normal tissues,
and are expressed in many cancers. These tumor antigens may
66 Poster Session Irender SP cells susceptible to T cell mediated destruction indicating
that T cell therapy may have a powerful effect on drug resistant tu-
mor cells when used as adjunct therapy.178
IMPROVED SURVIVAL FOR PATIENTS UNDERGOING AUTOLOGOUS
STEM CELL TRANSPLANT IN FIRST OR LATER REMISSION FOR PRIMARY
CNS LYMPHOMA
Johnston, P.B., O’Neill, B.P., Ansell, S.M., Inwards, D.J., Porrata, L.F.,
Micallef, I.N.M. Mayo Clinic, Rochester, MN.
Background: Survival for patients with primary CNS lymphoma
(PCNSL), in general, is poor with patients requiring frequent che-
motherapy treatments or receiving whole-brain radiation therapy,
which can potentially result in significant neurologic decline and
dementia. Because of the improved survival of high risk patients
with aggressive lymphoma undergoing autologous stem cell trans-
plant (ASCT), we began ASCT for patients with PCNSL in first
or later remission with chemotherapy sensitive disease. We now up-
date the outcomes of patients who have had at least 100 day follow
up post ASCT. Baseline Characteristics: Between June, 2000 and
March, 2007, 16 patients underwent ASCT for PCNSL. Median
age at transplant was 50 years old (range 30–67). Median number
of prior treatments 2 (range 1–3). Median time from diagnosis to
transplant was 7.5 months (range 2.9 to 75.8). Median International
Extranodal Working Study Group Prognostic Score: 2 (range 0–3).
Disease status at transplant: First CR 6 patients, later CR or PR 10
patients. Median follow up from diagnosis was 45 months. Results:
Sixteen patients underwent ASCT for PCNSL and have a minimum
of 100 days follow-up. All patients received BEAM conditioning.
Median follow up post-transplant was 32 months (range 3–85
months). Eight patients have relapsed at a median of 217 days (range
40–1349). Of the patients who relapsed, two have died of disease
progression and the remaining five are alive after additional therapy.
Median overall survival from transplant has not been reached.
Three year overall and event free survival from transplant are
82% and 53%, respectively. Median progression free survival
from BMT was 45 months. Overall survival from diagnosis at 5
years was 83%. Conclusions: Although limited by patient selection
and retrospective biases, this review suggests that ASCT for
PCNSL demonstrates improved overall survival when compared
to historical controls with similar PCNSL Prognostic Scores (2
year survival for patients from diagnosis with PS 2–3 was 48% in
a prior published study). ASCT in first remission in patients with
PCNSL appears promising and may limit the need for additional
therapy which can be myelosuppressive or result in neurologic de-
cline, secondary to radiation therapy, in patients who are appropri-
ate candidates.179
ALLOGENEIC STEM CELL TRANSPLANTATION FOR POST-AUTOLOGOUS
STEM CELL TRANSPLANT RELAPSE IN HODGKIN LYMPHOMA: EXPERI-
ENCE AT A SINGLE CENTER
Oliva, J.L., Kelly, J.L., Liesveld, J.L., Becker, M.W., Phillips, G.L.,
Sensenig, E., Constine, L., Bernstein, S.H., Fisher, R.I.,
Friedberg, J.W. University of Rochester, Rochester, NY.
Autologous stem cell transplantation (ASCT) is the standard of
care for relapsed or refractory Hodgkin Lymphoma (HL) and has
been associated with long-term survival rates of approximately
40%. Data regarding post-ASCT HL relapse are sparse, particu-
larly with regard to subsequent allogeneic stem cell transplantation
(allo SCT). To explore the impact of allo SCT on post-ASCT re-
lapsed HL, we evaluated all adult cases from mid 1992 to mid
2007. Primary objectives of this descriptive retrospective study
were to determine transplant-related characteristics, survival and
the incidence of GVHD. Fifteen cases (7 females, 8 males) met
study entry criteria. Histology included NS (14) and MC (1); 5
had primary refractory HL. All initially received ABVD and salvage
regimens varied. BEAM was the most commonly administeredASCT conditioning regimen and 9 received post-ASCT radiation.
Median time to post-ASCT relapse was 8 months (range 1–49).
Pre-allo SCT disease status was: CR (2); sensitive (6); stable (5);
missing (2). Median age at allo SCT was 34.4 years (range 20.0–
54.3). Reduced intensity (RI) and ablative regimens were adminis-
tered in 13 and 2 cases, respectively. RI regimens comprised 3 major
categories: fludarabine and melphalan (7); pentostatin, TBI and
photopheresis (4); other (2). Donors were siblings (6) or unrelated
volunteers (9); 5 donor/recipient pairs were HLA mismatched.
GVHD prophylaxis included: tacrolimus or CSA plus MMF (7); ta-
crolimus and sirolimus (5); tacrolimus or CSA with mini-metho-
trexate (3). Seven patients are deceased with a median survival
post-allo SCT of 9 months (range 1–18). HL was the primary cause
of death for 4. Of the 8 surviving (median follow-up 8.5 months;
range 2–19), 2 have relapsed HL treated with further radiation or
donor leukocytes. Overall, 60% were treated for acute or chronic
GVHD and 4 of those surviving have extensive chronic GVHD.
Of these 4, 3 remain in remission more than 1-year after allo SCT.
Conclusions: Follow-up, survival, and complications in HL re-
lapsed after ASCT are largely under-reported in the literature. Pre-
vious evidence suggests a high TRM for HL after allo SCT utilizing
traditional ablative regimens, however, outcomes are lesser known
in a new era of RI options. There is literature to suggest that allo
SCT may afford a GV-HL effect that is potentially curative, but
data are currently lacking to support a standard treatment approach.
Novel approaches and/or therapeutic clinical trials are needed.180
A SUCCESSFUL TREATMENT STRATEGY FOR PATIENTS WITH T-NHL:
ALLOGENEIC TRANSPLANTATION AFTER BEAM-ALEMTUZUMAB
CONDITIONING
Gramatzki, M.1, Schade, H.1, Schrauder, A.2, Humpe, A.1, Repp, R.1.
1University of Kiel, Kiel, Germany; 2University of Kiel, Kiel, Germany.
For patients with relapsed or refractory T-cell lymphomas the
prognosis is grim and no standard treatment strategy exists. In ad-
dition, mature T/NK-cell-lymphomas are an infrequent and het-
erogeneous group of lymphoid tumors. Ten patients with
relapsed T-cell Non-Hodgkin’s lymphoma (NHL) were treated
with allogeneic stem cell transplantation (SCT) after 1 to 2 cycles
of CLAEG (cladribine, cytarabine, etoposide/etopophos and G-
CSF) induction therapy immediately followed by conditioning
with BEAM (carmustine, cytarabine, etoposid/etopophos, melpha-
lan) combined with alemtuzumab (Campath-1H). The following
subtypes were included: 5 peripheral T-cell lymphomas (not other-
wise specified), 2 angioimmunoblastic, 1 ALK negative anaplastic
large cell, 1 extranodal NK/nasal type and 1 enteropathy-type T-
cell lymphoma. All patients had at least 2 different treatment regi-
mens previously. After 1 to 2 cycles of induction chemotherapy
with CLAEG, one patient achieved a CR, 6 patients a PR and 3
had SD. Conditioning with BEAM combined with alemtuzumab
was well tolerated. Seven patients received peripheral blood stem
cells (PBSC) from HLA-identical unrelated donors and 2 from
matched sibling donors, 1 patient received bone marrow from an
HLA one-allele mismatched unrelated donor. Engraftment was
rapid and the treatment well tolerated. There were 4 cases of grade
4 mucositis, 2 cases of sepsis in neutropenia, and 1 case of grade IV
liver toxicity. Prophylaxis for graft-versus-host disease (GvHD)
consisted of cyclosporine A and MTX or mycophenolate mofetil.
No grade III or IV acute GvHD was seen and only 3 patients pre-
sented with grade II GvHD. Two patients experienced limited
chronic GvHD. Asymptomatic CMV reactivation was found in 4
cases and all were treated successfully. Late infections occurred in
four patients, including CMV infection, viral enteritis, aspergillus
pneumonia and streptococcal sepsis. All patients achieved a CR af-
ter allogeneic transplantation. Currently, 3 patients have relapsed.
One patient died in CR on day 233 post transplantation due to as-
piration pneumonia caused by non-malignant bowel stenosis. All
other patients remained in CR for up to 261 months. This treat-
ment approach with CLAEG induction followed by conditioning
with BEAM combined with alemtuzumab shows a surprisingly
good outcome in a group of T-cell NHL patients with a very
poor prognosis. Allogeneic SCT with this strategy seems to be
a promising therapeutic option for these patients.
